Sagimet Biosciences presents two denifanstat posters at AASLD

Sagimet Biosciences (SGMT) announced the presentation of two posters at the American Association for the Study of Liver Disease, AASLD – The Liver Meeting 2025, taking place November 7-11, 2025 in Washington, DC. The first poster, “Denifanstat elicited a significant greater than or equal to2-stage improvement in fibrosis in F3 MASH patients, and improved liver fibrosis and biomarkers in qFibrosis stage 4 MASH patients: secondary analysis of phase 2b FASCINATE-2 trial.” In a secondary analysis of the Phase 2b FASCINATE-2 clinical trial, AI-based digital pathology was used to identify a subpopulation of MASH patients with advanced fibrosis, defined as qFibrosis stage 4, and to explore liver histology improvement with denifanstat in this subset. The second poster, “Spatial Computational Histology Stratified Denifanstat Responders in the Phase 2b FASCINATE-2 MASH Trial.” In this analysis, spatial computational histology relying on baseline fibrosis features was used to predict response to denifanstat. Quantitative single-fiber traits and clustering revealed fibrosis phenotypes that predicted denifanstat response, supporting that computational pathology could be leveraged for response stratification.